Stock Events

Stock Events

Cotinga Pharmaceuticals 

$0
2
+$0+0% Monday 00:00

Statistics

Day High
0
Day Low
0
52W High
0
52W Low
0
Volume
6,500
Avg. Volume
0
Mkt Cap
0
P/E Ratio
-
Dividend Yield
-
Dividend
-

Earnings

1AprExpected
Q1 2018
Q2 2018
Q3 2018
Q1 2019
Q2 2019
Q3 2019
Q1 2020
-0.07
-0.05
-0.03
-0.01
Expected EPS
N/A
Actual EPS
-0.0184

Financials

-Profit Margin
Unprofitable
2013
2014
2015
2016
2017
2018
0Revenue
-2.05MNet Income

People Also Follow

This list is based on the watchlists of people on Stock Events who follow COTQF. It's not an investment recommendation.
Alphabet
79493
GOOGL
Apple
69146
AAPL
Microsoft
64576
MSFT
Amazon
60260
AMZN

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
AMGEN
AMGN
Mkt Cap160.66B
Amgen is a biotechnology firm developing novel therapies in areas overlapping with Cotinga's focus on cancer treatments.
Bristol-Myers Squibb
BMY
Mkt Cap93.79B
Bristol-Myers Squibb is a global biopharmaceutical company with a strong portfolio in oncology, competing in the cancer treatment space.
Merck
MRK
Mkt Cap214.76B
Merck is known for its extensive research and development in oncology, directly competing with Cotinga's cancer therapies.
Pfizer
PFE
Mkt Cap140.15B
Pfizer operates in various therapeutic areas including oncology, making it a direct competitor in cancer drug development.
Lilly(Eli) &
LLY
Mkt Cap772.28B
Eli Lilly and Company has a significant focus on cancer research and drug development, aligning as a competitor in the oncology sector.
Gilead Sciences
GILD
Mkt Cap148.78B
Gilead Sciences is involved in the development of oncology treatments, competing with Cotinga Pharmaceuticals in the cancer therapy market.
Abbvie
ABBV
Mkt Cap385.18B
AbbVie has a growing presence in oncology through both research and strategic acquisitions, positioning it as a competitor.
Regeneron Pharmaceuticals
REGN
Mkt Cap68.5B
Regeneron Pharmaceuticals focuses on innovative biopharmaceuticals, including cancer treatments, competing in the same therapeutic area.
Astrazeneca
AZN
Mkt Cap256.58B
AstraZeneca has a strong pipeline in oncology, directly competing with Cotinga Pharmaceuticals in developing cancer therapies.
Novartis
NVS
Mkt Cap237.61B
Novartis is a global healthcare company with a robust focus on oncology, making it a key competitor in cancer drug development.

About

Cotinga Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer and other unmet medical needs. The company's lead compound is COTI-2, an oral small molecule targeting p53 a tumor suppressor gene. It also develops COTI-219, an oral small molecule compound targeting the mutant forms of KRAS without inhibiting normal KRAS functions. Cotinga Pharmaceuticals Inc. has a research collaboration with St. Vincent's University Hospital to evaluate COTI-2 in combination with eribulin in patients with triple negative metastatic breast cancer. The company was formerly known as Critical Outcome Technologies Inc. and changed its name to Cotinga Pharmaceuticals Inc. in January 2018. Cotinga Pharmaceuticals Inc. is based in Toronto, Canada.
Show more...
CEO
Ms. Alison D. Silva MA, MS
Country
CA
ISIN
CA22164W1059

Listings

0 Comments

Share your thoughts

FAQ

What is Cotinga Pharmaceuticals stock price today?▼
The current price of COTQF is $0 USD — it has increased by +0% in the past 24 hours. Watch Cotinga Pharmaceuticals stock price performance more closely on the chart.
What is Cotinga Pharmaceuticals stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Cotinga Pharmaceuticals stocks are traded under the ticker COTQF.
What were Cotinga Pharmaceuticals earnings last quarter?▼
COTQF earnings for the last quarter are -0.02 USD per share, whereas the estimation was N/A USD resulting in a N/A surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Cotinga Pharmaceuticals revenue for the last year?▼
Cotinga Pharmaceuticals revenue for the last year amounts to 0 USD.
What is Cotinga Pharmaceuticals net income for the last year?▼
COTQF net income for the last year is -2.05M USD.
In which sector is Cotinga Pharmaceuticals located?▼
Cotinga Pharmaceuticals operates in the Health Care sector.
When did Cotinga Pharmaceuticals complete a stock split?▼
The last stock split for Cotinga Pharmaceuticals was on June 30, 2017 with a ratio of 1:10.
Where is Cotinga Pharmaceuticals headquartered?▼
Cotinga Pharmaceuticals is headquartered in Toronto, CA.